Spero Therapeutics, Inc.SPROEarnings & Financial Report
Nasdaq · Health Care · Pharmaceutical Preparations
Revenue
$114.0K
Gross Profit
N/A
Operating Profit
$-19.1M
Net Profit
$-17.9M
Gross Margin
N/A
Operating Margin
-16720.2%
Net Margin
-15668.4%
YoY Growth
-57.6%
EPS
$-0.33
Spero Therapeutics, Inc. Q2 FY2024 Financial Summary
Spero Therapeutics, Inc. reported revenue of $114.0K (down 57.6% YoY) for Q2 FY2024, with a net profit of $-17.9M (down 50.1% YoY) (-15668.4% margin).
Key Financial Metrics
| Total Revenue | $114.0K |
|---|---|
| Net Profit | $-17.9M |
| Gross Margin | N/A |
| Operating Margin | -16720.2% |
| Report Period | Q2 FY2024 |
Spero Therapeutics, Inc. Annual Revenue by Year
Spero Therapeutics, Inc. annual revenue history includes year-by-year totals (for example, 2025 revenue was $12.6M).
| Year | Annual Revenue |
|---|---|
| 2025 | $12.6M |
| 2024 | $371.0K |
| 2023 | $933.0K |
| 2022 | $2.5M |
Spero Therapeutics, Inc. Quarterly Revenue & Net Profit History
Spero Therapeutics, Inc. results over the last 8 reported quarters, including revenue, net profit and year-over-year growth.
| Quarter | Revenue | Revenue YoY | Net Profit | Net Margin |
|---|---|---|---|---|
| Q4 FY2025 | $12.6M | +24080.8% | $31.5M | 250.7% |
| Q3 FY2025 | $0 | — | $-7.4M | N/A |
| Q2 FY2025 | $0 | — | $-1.7M | N/A |
| Q1 FY2025 | $12.0K | -91.4% | $-13.9M | -115550.0% |
| Q4 FY2024 | $52.0K | -76.7% | N/A | N/A |
| Q3 FY2024 | $65.0K | -70.2% | $-17.1M | -26380.0% |
| Q2 FY2024 | $114.0K | -57.6% | $-17.9M | -15668.4% |
| Q1 FY2024 | $140.0K | -37.2% | $-12.7M | -9049.3% |
Income Statement
| Q1 2024 | Q2 2024 | Q3 2024 | Q4 2024 | Q1 2025 | Q2 2025 | Q3 2025 | Q4 2025 | |
|---|---|---|---|---|---|---|---|---|
| Revenue | $140000 | $114000 | $65000 | $52000 | $12000 | $0 | $0 | $12.6M |
| YoY Growth | -37.2% | -57.6% | -70.2% | -76.7% | -91.4% | N/A | N/A | 24080.8% |
Balance Sheet
| Q1 2024 | Q2 2024 | Q3 2024 | Q4 2024 | Q1 2025 | Q2 2025 | Q3 2025 | Q4 2025 | |
|---|---|---|---|---|---|---|---|---|
| Assets | $167.7M | $149.9M | $135.2M | $110.5M | $77.7M | $62.1M | $54.2M | $68.9M |
| Liabilities | $71.5M | $69.4M | $69.7M | $64.4M | $43.9M | $29.3M | $27.7M | $9.9M |
| Equity | $96.2M | $80.5M | $65.5M | $46.1M | $33.8M | $32.8M | $26.5M | $59.0M |
Cash Flow
| Q1 2024 | Q2 2024 | Q3 2024 | Q4 2024 | Q1 2025 | Q2 2025 | Q3 2025 | Q4 2025 | |
|---|---|---|---|---|---|---|---|---|
| Operating CF | $5.9M | $-18.7M | $12.8M | $-23.4M | $-4.0M | $-17.7M | $17.4M | $-8.4M |